© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
July 29, 2021
Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.
Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.
July 20, 2021
Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.
Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.
July 15, 2021
MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.
Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.
July 06, 2021
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.
July 01, 2021
Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.
Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.